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RAS. 15 In this double-blind multicenter 
trial, 281 patients with type 2 diabetic 
nephropathy and albuminuria have been 
randomized equally to 1 or 2   g paricalci-
tol per day or placebo. Th e fi nal results of 
this largest multicenter trial are yet to be 
published. 
 Our present knowledge of vitamin D 
calls for at least maintaining adequate 
stores of vitamin D for bone health and 
perhaps cardiovascular, immunological, 
and renal health among patients with 
CKD. What should be an adequate level of 
vitamin D itself remains poorly defi ned, 
but a 25-hydroxyvitamin D level greater 
than 30 ng / ml is considered adequate. 
Although VDRAs reduce proteinuria, a 
strong surrogate for future renal disease 
progression, whether VDRAs can prolong 
the time to end-stage renal disease has not 
been addressed by any of the existing stud-
ies. Accordingly, whether VDRAs should 
become the standard of care among 
patients with CKD remains to be answered 
by well-designed controlled clinical trials. 
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 Th e health-related quality of life (HRQOL) 
of patients with chronic kidney disease 
(CKD) has recently been the focus of much 
attention. 1 The association of impaired 
HRQOL measures with higher hospitaliza-
tion and mortality rates is well docu-
mented. 2,3 And, importantly, HRQOL 
measures are being viewed as valid end 
points of clinical trials involving the care of 
CKD patients. 1,4 It is in fact now mandated 
that HRQOL be monitored in the United 
States as part of the conditions of coverage 
for end-stage renal disease (ESRD) patients 
by the Centers for Medicare  & Medicaid 
Services. 1 Th e high incidence of clinical 
depression and the striking presence of 
depressive symptoms in CKD patients have 
also been the subject of several recent 
reviews and studies. 3,5 Th ese investigations 
have primarily focused attention on the 
patient with ESRD. 3,5 
 Th e remarkably high prevalence of CKD 
in the general population has been empha-
sized and is provoking much  discussion 
among nephrologists about how to coor-
dinate the care of these patients to slow the 
progression of their CKD, reduce their 
high cardiovascular complication rate, 
manage the various CKD-specifi c comor-
bidities (for example, anemia, CKD – min-
eral and bone disorder, hypertension), 
provide education concerning CKD and 
the implications of ESRD therapy, and 
improve the overall medical care of these 
complex patients. But the impairment of 
the HRQOL of CKD patients not on dialy-
sis has only recently begun to be system-
atically evaluated. 6 – 8 Th ese preliminary 
studies suggest that there is a signifi cant 
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 The paper by Fischer  et al. focuses attention on the striking prevalence 
of depressive symptoms in non-dialyzed chronic kidney disease 
patients. The presence of depressive symptoms correlated with various 
health-related quality of life measures and economic status. These 
findings suggest that our view of providing care needs to broaden to 
incorporate not only thorough medical care, education, and dietary 
support, but also psychosocial assessments. They also underscore the 
importance of providing this care to those who are most vulnerable. 
 Kidney International (2010)  77, 945 – 947.  doi: 10.1038/ki.2010.78 
 1 Hospital of St Raphael ,  New Haven ,  Connecticut , 
 USA ;   2 Department of Nephrology, Yale University , 
 New Haven ,  Connecticut ,  USA  and  3 Renal Research 
Institute ,  New Haven ,  Connecticut ,  USA  
 Correspondence: Fredric O. Finkelstein, 136 
Sherman Avenue, New Haven, Connecticut 06511, 
USA. E-mail:  fof@comcast.net 
commentar y
946   Kidney International (2010) 77 
impairment in a variety of HRQOL meas-
ures and that there is a high incidence of 
clinical depression among these patients. 
Th us, Mujais  et al. , in a cross-sectional 
analysis of 1200 CKD patients, have shown 
a progressive decline of various HRQOL 
measures as CKD progresses. 6 Hedayati 
 et al. performed structured interviews with 
272 CKD patients (the majority stage 3 
and stage 4) and noted a 21 % incidence of 
clinical depression. 7 And the paper by 
Fischer  et al. 8 in this issue of  Kidney Inter-
national underscores the remarkably high 
incidence of depressive symptoms in CKD 
patients — 26 % of 628 African-American 
patients enrolled in the African American 
Study of Kidney Disease and Hypertension 
Cohort Study had Beck Depression Inven-
tory (BDI) scores greater than 14 at the 
time of enrollment. It is important to 
remember that establishing a diagnosis of 
clinical depression requires that a struc-
tured interview be performed to fulfi ll the 
standard Diagnostic and Statistical Manual 
of Mental Disorders IV criteria for a clini-
cal depression; such interviews were not 
performed in the study by Fischer  et al. 8 
But a prior study by Hedayati  et al. in 
which CKD patients not on dialysis com-
pleted a BDI questionnaire and then par-
ticipated in a structured interview 
established that a BDI score of 11 or greater 
had 89 % sensitivity and 88 % specifi city for 
diagnosing clinical depression. 7 Th us, it 
is likely that the vast majority of the 
patients studied by Fischer  et al. 8 would 
in fact meet the criteria for a clinical 
depression if interviewed — although it 
would be of interest to confirm that 
Hedayati ’ s fi ndings were substantiated in 
this study population. 
 Th e fi ndings of Fischer  et al. 8 are in some 
ways not surprising. Th e high incidence of 
depressive symptoms in patients with 
chronic disease is well documented. For 
example, in a large World Health Organi-
zation study examining the incidence of 
self-reported depressive symptoms, nearly 
25 % of patients with two or more medical 
conditions (as many CKD patients have) 
reported having depressive symptoms. 9 
 Why then are these fi ndings so impor-
tant? First, the study directs attention to the 
psychosocial diffi  culties of the patient with 
CKD and obligates us to expand our view 
of developing strategies for the manage-
ment of these patients. The well-docu-
mented association of depressive symptoms 
with adverse medical outcomes, vascular 
disease, poor compliance, and infl amma-
tion underscores the adverse impact that 
this problem can have on the outcomes of 
CKD patients. 1 Second, the study draws 
our attention to the association between 
depressive symptoms and other HRQOL 
measures, including satisfaction with life 
and selected domains on the Short Form 
(36) Health Survey (Mental and Physical 
Health Component Scores). And, third, the 
study demonstrates an association between 
low income and unemployment and 
depressive symptoms; that is, the 
 disadvantaged are the ones most in need of 
support and intervention. 
 As attention is now being increasingly 
focused on the comprehensive manage-
ment of CKD patients not on dialysis, it 
is clear that an expanded view needs to 
be taken of how this care is organized 
( Figure 1 ). We must provide more than 
just detailed management of the complex 
medical complications presented by 
these patients. Structured education pro-
grams are being developed and inte-
grated into standard CKD care to enable 
patients to become active and informed 
participants in their treatment program. 
The importance of this education in 
improving patient compliance and med-
ical outcomes and facilitating the transi-
tion to ESRD care is now recognized. 
Previous studies have clearly indicated 
that patients receiving traditional rou-
tine care in the United States and Canada 
do not develop an understanding and 
knowledge of the basics of CKD care and 
modality options for ESRD. 10 And it is 
not possible during routine physician 
visits to provide adequate information to 
permit patients to understand the com-
plexities of dietary variables that may 
impact on their outcomes; dieticians 
need to directly participate in patient 
care. In the United States, the Centers for 
Medicare  & Medicaid Services have now 
agreed to provide fi nancial support for 
both of these arenas (dietary support and 
patient education), following the lead of 
other countries that have had more 
enlightened views of coordinating and 
providing more comprehensive health-
care services. Moreover, the paper by 
Fischer  et al. 8 draws our attention to the 
psychosocial problems of patients with 
CKD. This arena also needs to be 
addressed to permit us to off er thorough 
and optimal care to these patients. 
Addressing the psychosocial problems of 
patients and their families needs to be 
incorporated into the routine care of 
CKD patients. Additional support needs 
to be provided to permit this to occur. 
Th e importance of addressing these psy-
chosocial problems in terms of  improving 
 Figure 1  |  Comprehensive care of the CKD patient: an expanded view. CKD-MBD, CKD – mineral 
and bone disorder. 
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medical outcomes, reducing costs, and 
enhancing patients ’ HRQOL needs addi-
tional emphasis and attention. 
 Lessons from the care of ESRD patients 
in this regard may be helpful. A high inci-
dence of clinical depression in ESRD 
patients is well documented. 1,5 Various 
treatment options have now been shown 
to be helpful in reducing depressive symp-
toms. 1,5 Th ese options include both phar-
macological and non-pharmacological 
therapies, including cognitive-behavioral 
therapy, exercise, and modifi cations in the 
dialysis treatment regimen. 1,5 It has been 
proposed that ESRD patients routinely be 
screened with validated questionnaires 
inquiring about depressive symptoms and 
that those patients with scores above 
 certain predetermined values have direct 
interviews to screen for clinical depres-
sion. 1,5 Appropriate treatment options can 
then be discussed with the patient. Could 
a similar algorithm be developed for CKD 
patients? 
 Fischer  et al. 8 emphasize that it is the 
fi nancially disadvantaged who need the 
most support — perhaps sending a mes-
sage to health-care policy makers in the 
United States about the need for health-
care reform. It is this population (the 
unemployed and low-wage earners) who 
oft en lack proper health insurance and 
thus are deprived of the health care that 
they so need. We must ask ourselves to 
what extent the high incidence of ESRD 
in these groups of patients refl ects their 
limited access to care rather than a genetic 
predisposition. 
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 Th erapeutic interventions are generally 
based on an evaluation of clinical data, 
diagnostic information, and availability 
of the therapy and ancillary resources. 
Th ere is an increasing appreciation that 
the timing of therapy is an important 
determinant of outcomes, particularly if 
the intervention targets a specifi c mech-
anism or pathway involved in the disease 
process. For instance, management of 
acute chest pain syndromes and stroke 
emphasizes early interventions within a 
few hours from the event. Th erapy is tar-
geted to mitigate the eff ects of platelet 
adherence and activation, which have 
been implicated in the development of 
the ischemic injury. Th ese strategies have 
dramatically altered outcomes and 
resulted in improved survival and have 
further demonstrated the time-depend-
ent relationship of the benefi t. On the 
basis of these observations, it is apparent 
that interventions based on  ‘ windows of 
opportunity ’ coupled with targeted ther-
apy are an important construct for man-
aging diseases. However, in kidney 
disease, these approaches are applied 
only in a limited fashion. Unlike myocar-
dial infarction and stroke, kidney disease 
is largely asymptomatic, and kidney 
injury may be discovered only late in the 
course. Consequently, precise timing has 
usually not been a major focus, particu-
larly in chronic kidney disease (CKD), 
since the progression generally occurs 
over weeks and months. Additionally, 
although several targets have been iden-
tifi ed, few are actually used — for exam-
ple, angiotensin-converting enzyme 
inhibitors for slowing progression. Simi-
larly, in acute kidney injury (AKI), a 
sense of therapeutic nihilism has pre-
vailed, with no clear therapeutic options 
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 Whether and when to intervene and with which therapeutic agent are 
key questions physicians face daily in managing patients. Biomarkers 
are emerging to define the course of acute kidney injury and offer an 
opportunity to provide targeted interventions. The EARLYARF study by 
Endre  et al. provides a glimpse of the challenges and opportunities that 
lie ahead. 
 Kidney International (2010)  77, 947 – 949.  doi: 10.1038/ki.2010.79 
 1 Division of Nephrology and Hypertension, 
Department of Medicine, University of California , 
 San Diego ,  California ,  USA  
 Correspondence: Ravindra L. Mehta, Department 
of Medicine, University of California, San Diego, 
200 W. Arbor Drive, Mail Code 8342, San Diego, 
California 92103, USA. E-mail:  rmehta@ucsd.edu 
